Genotype B and Younger Patient Age Associated with Better Response to Low-Dose Therapy: A Trial with Pegylated/Nonpegylated Interferon- -2b for Hepatitis B e Antigen--Positive Patients with Chronic Hepatitis B in China
Clinical Infectious Diseases2007Vol. 44(4), pp. 541–548
Citations Over TimeTop 10% of 2007 papers
Hong Zhao, Fuat Kurbanov, M.-B. Wan, Y.-K. Yin, Jun Niu, Jin Hou, Lihui Wei, G.-Q. Wang, Yasuhito Tanaka, M. Mizokami, Si Chen
Abstract
The choice of low-dose IFN regimen might be a relevant clinical option to reduce the cost and adverse effects of therapy for younger patients with chronic HBV infection and genotype B infection in countries where it is prevalent.
Related Papers
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2005)5 cited
- → 576 Early detection of depressive symptoms during treatment with pegylated interferon α-2 and ribavirin in euthymic chronic hepatitis C patients(2006)
- → 907 IS SHORT TIME COMBINED THERAPY WITH PEGYLATED INTERFERON PLUS RIBAVIRIN EFFECTIVE IN PATIENTS WITH ACUTE HEPATITIS C?(2013)
- → Dermatological Side Effects in a Patient with Hepatitis C Infection During Treatment with Pegylated Interferon/Ribavirin+Telaprevir: A Case Report(2014)
- → Pegylated Interferon, Ribavirin, and Sofosbuvir Combination versus Pegylated Interferon, Ribavirin in the Management of Chronic Hepatitis C Egyptian Patients(2017)